Matthew Roe, MD, Named ED of the Colorado Prevention Center.

14:44 EDT 7 Aug 2017 | Colorado BioScience

Matthew T. Roe, MD, MHS has been named as the next Executive Director of the Colorado Prevention Center (CPC), and will be appointed as Professor of Medicine in the Division of Cardiology, Department of Medicine, University of Colorado School of Medicine with an expected starting date of January 1, 2018.

Dr. Roe is currently a Professor of Medicine in the Division of Cardiology at Duke University Medical Center and the Duke Clinical Research Institute (DCRI). His responsibilities there include serving as the Faculty Director of the Megatrials group, the DCRI Research Fellowship Director, and the Faculty Director of the DCRI Think Tank Series.

“We are excited to have someone as talented and experienced as Dr. Roe joining us at CPC,” said William R. Hiatt, MD, President of CPC. Dr. Hiatt added “Under Dr. Roe’s leadership we anticipate that the CPC and University of Colorado will develop collaborations with other Academic Research Organizations (ARO’s) and Academic Medical Centers to create tremendous new opportunities for future innovative clinical research.”

Dr. Roe has extensive experience in the design, conduct, and reporting of large cardiovascular outcome trials as he has developed specific expertise in innovative, pragmatic trial designs. He currently serves as the co-principal investigator for the ADAPTABLE Trial (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) that is evaluating low- vs. high-dose aspirin dose for thousands of patients with atherosclerotic cardiovascular disease. The trial is funded through a Patient-Centered Outcomes Research Institute (PCORI) Award. He has also served in leadership positions in numerous other cardiovascular clinical trials and national cardiovascular registries. Additionally, Dr. Roe has led the growth and development of the DCRI Research Fellowship which focuses upon training the next generation of clinical investigators across medical specialties and therapeutic areas.

“I am very excited about working in the innovative culture at CPC with a great team of colleagues to promote the mission and evolution of the organization,” said Dr. Roe. “The infrastructure and opportunities for collaboration and integration of clinical research activities are tremendous with CPC and the University of Colorado.”

At CPC and the University of Colorado, Dr. Roe plans to contribute to the expansion of clinical research activities across the Anschutz Medical Campus and the University’s partner health system, where the clinical trials expertise of CPC can serve as a foundation for building a larger University clinical research platform that encompasses health services research, electronic health record (EHR)-facilitated, pragmatic research, large-scale site-based research across specialties, and innovative research approaches including digital health applications, patient engagement, and streamlined research processes designed to increase value and reduce costs. He also plans to collaborate with researchers and educators at CPC and the University of Colorado to establish a dedicated clinical research training program that involves trainees (students, residents, and fellows) in all aspects of clinical research.

Dr. Hiatt intends to remain as full-time faculty at the University of Colorado in Vascular Medicine in the Division of Cardiology and support the research and training missions of CPC.

Original Article: Matthew Roe, MD, Named ED of the Colorado Prevention Center.


More From BioPortfolio on "Matthew Roe, MD, Named ED of the Colorado Prevention Center."

Quick Search

Relevant Topics

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...